Bioequivalence, safety and immunogenicity of BI 695501, an adalimumab biosimilar candidate, compared with the reference biologic in a randomized, double-blind, active comparator phase I clinical study (VOLTAIRE®-PK) in healthy subjects - Concepedia

Concepedia

Publication | Open Access

Bioequivalence, safety and immunogenicity of BI 695501, an adalimumab biosimilar candidate, compared with the reference biologic in a randomized, double-blind, active comparator phase I clinical study (VOLTAIRE®-PK) in healthy subjects

DOI Full Paper Access

59

Citations

15

References

2016

Year

Christopher Wynne, Mario Altendorfer, Ivo Sonderegger, Lien Gheyle, R. B. Ellis‐Pegler, Susanne Buschke, Benjamin Lang, Deepak Assudani, Sandeep N. Athalye, Niklas Czeloth

Expert Opinion on Investigational Drugs

Abstract

2013-003722-84 (EudraCT) and NCT02045979.

References

	Year	Citations

Page 1